«We wanted to identify some potential therapeutic targets that are common not just to one but to multiple forms of retinitis
pigmentosa at late - stage disease, when it is more likely to be clinically diagnosed in a patient population.»
Not exact matches
Through the actions of its legislature and the relevant regulatory agencies, Illinois sets numerous conditions on that use: myopic people have to wear glasses or contact lenses while driving; people with retinitis
pigmentosa are forbidden from driving
at night; teenagers must reach a certain age and demonstrate certain skills before they obtain driver's licenses; people with a habit of driving after knocking back a dozen Budweisers lose their licenses.
Rather than looking
at what distinguished two forms of retinitis
pigmentosa, or RP, a progressive blinding disease, they looked for what they had in common: specifically, what genes were expressed
at the later stages of disease.
«Any improvement in people with retinitis
pigmentosa is big because it's an inexorable disease where you gradually go blind,» says Julia Haller, a professor of ophthalmology
at Johns Hopkins University who has worked with the implant.
His initial RPB - funded research was aimed
at furthering the vision research community's understanding of the mechanisms underlying macular degeneration, retinitis
pigmentosa, and other retinal degenerations.
At the ISSCR 2016 meeting in San Francisco, attendees heard two inspirational stories from Kristin Macdonald and Adrienne Bell - Cors of what it's like to live with diseases such as retinitis
pigmentosa (RP), and sickle cell disease, respectively.
This project aims
at the transplantation of retinal cells derived from human embryonic stem cells in patients with retinitis
pigmentosa.